Skip to content
Poster

Reproducible hepatoprotective effects and clinical translatability of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Background & Aim: 

The glucagon-like peptide-1 (GLP-1) analogue semaglutide has been reported to promote resolution of MASH and improve fibrosis stage in a recent clinical phase 3 trial (ESSENCE). The present study aimed to evaluate robustness of outcomes of long-term semaglutide treatment in the GAN diet-induced obese (DIO) mouse model of biopsyconfirmed MASH and fibrosis with reference to clinical endpoints

Subjects
GAN DIO-MASH mouseMouseBody weightBlood biochemistryMetabolic dysfunction-associated steatohepatitisGLP-1 receptorHistopathology scoreGLP-1GLP-1 receptor agonistLiver biopsyLiver morphometrySemaglutide

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top